239 related articles for article (PubMed ID: 24213580)
1. Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
[TBL] [Abstract][Full Text] [Related]
4. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
[TBL] [Abstract][Full Text] [Related]
5. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
6. [Detection of FUS-CHOP fusion gene in paraffin-embedded tissues and its clinicopathologic significance for myxoid/round cell liposarcomas].
Xiang H; Wang J; Sun MH; Lu L; Shui RH; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):28-32. PubMed ID: 15796878
[TBL] [Abstract][Full Text] [Related]
7. FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway.
Tornin J; Hermida-Prado F; Padda RS; Gonzalez MV; Alvarez-Fernandez C; Rey V; Martinez-Cruzado L; Estupiñan O; Menendez ST; Fernandez-Nevado L; Astudillo A; Rodrigo JP; Lucien F; Kim Y; Leong HS; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2018 Jan; 20(1):44-56. PubMed ID: 29190494
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
[TBL] [Abstract][Full Text] [Related]
9. Detection of TLS/FUS-CHOP fusion transcripts in a case of oral liposarcoma.
Rivero ER; Mesquita RA; de Sousa SC; Nunes FD
Ann Diagn Pathol; 2006 Feb; 10(1):36-8. PubMed ID: 16414544
[TBL] [Abstract][Full Text] [Related]
10. The intriguing patterns of tumor response to trabectedin.
Sanfilippo R; Casali PG
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
[TBL] [Abstract][Full Text] [Related]
11. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
[TBL] [Abstract][Full Text] [Related]
12. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
[TBL] [Abstract][Full Text] [Related]
13. PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
Charytonowicz E; Terry M; Coakley K; Telis L; Remotti F; Cordon-Cardo C; Taub RN; Matushansky I
J Clin Invest; 2012 Mar; 122(3):886-98. PubMed ID: 22293175
[TBL] [Abstract][Full Text] [Related]
14. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
[TBL] [Abstract][Full Text] [Related]
16. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.
Wu H; Xia L; Xu H
Biochem Genet; 2022 Jun; 60(3):1095-1106. PubMed ID: 34792704
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
18. A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma.
Patil N; Ahmed Kabeer Rasheed S; Abba M; Hendrik Leupold J; Schwarzbach M; Allgayer H
Int J Cancer; 2014 Jun; 134(12):2808-19. PubMed ID: 24285420
[TBL] [Abstract][Full Text] [Related]
19. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
[TBL] [Abstract][Full Text] [Related]
20. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion.
Bode-Lesniewska B; Frigerio S; Exner U; Abdou MT; Moch H; Zimmermann DR
Genes Chromosomes Cancer; 2007 Nov; 46(11):961-71. PubMed ID: 17647282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
